BofA moves to No Rating from Underperform on IGM Biosciences (IGMS) after the company announced an agreement to be acquired by Concentra Biosciences for $1.247 per share in cash and a variable non-tradable contingent value right. IGM shares are no longer trading on fundamentals following the deal announcement, the analyst says.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IGMS:
- IGM Biosciences Announces Merger with Concentra Biosciences
- IGM Biosciences be acquired by Concentra for $1.247 in cash per share
- IGM Biosciences Faces Nasdaq Non-Compliance Notice
- IGM Biosciences price target lowered to $1 from $2 at Truist
- IGM Biosciences Reports Increased Net Loss Amid Strategic Focus